Syndax Pharmaceuticals (SNDX) Cash from Operations (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Cash from Operations of 50345000.0 for Q1 2026, up 47.1% year-over-year from 34226068.84 in Q1 2025, and up 27.55% quarter-over-quarter from 69488000.0 in Q4 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) Cash from Operations (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Cash from Operations history runs 12 years deep, the most recent figure standing at 50345000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 47.1% year-over-year to 50345000.0; the TTM figure through Mar 2026 stood at 278163000.0 (up 2.92% YoY), while the FY2025 annual figure was 322980000.0, down 17.49% from the prior year.
- Cash from Operations for Q1 2026 stood at 50345000.0, up from 69488000.0 in the prior quarter.
- The five-year high for Cash from Operations was 22894000.0 in Q4 2022, with the low at 95162000.0 in Q1 2025.
- The 5-year median for Cash from Operations is 50345000.0 (2026), against an average of 55441411.76.
- The sharpest annual moves came in 2022 and 2026: Cash from Operations slumped 122.73% in 2022, then surged 47.1% in 2026.
- Syndax Pharmaceuticals' Cash from Operations stood at 22894000.0 in 2022, then tumbled by 80.61% to 41349000.0 in 2023, then sank by 38.79% to 57388000.0 in 2024, then retreated by 21.08% to 69488000.0 in 2025, then gained by 27.55% to 50345000.0 in 2026.
- Business Quant data shows SNDX's Cash from Operations at 50345000.0 in Q1 2026, 69488000.0 in Q4 2025, and 70535000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn | -30.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -30.27 Mn |
| Mar 31, 2026 | -50.35 Mn |
| Dec 31, 2025 | -69.49 Mn |
| Sep 30, 2025 | -70.54 Mn |
| Jun 30, 2025 | -87.80 Mn |
| Mar 31, 2025 | -95.16 Mn |
| Dec 31, 2024 | -57.39 Mn |
| Sep 30, 2024 | -62.32 Mn |
| Jun 30, 2024 | -71.65 Mn |
| Mar 31, 2024 | -83.55 Mn |
| Dec 31, 2023 | -41.35 Mn |
| Sep 30, 2023 | -44.65 Mn |
| Jun 30, 2023 | -35.37 Mn |
| Mar 31, 2023 | -39.23 Mn |
| Dec 31, 2022 | -22.89 Mn |
| Sep 30, 2022 | -28.54 Mn |
| Jun 30, 2022 | -40.31 Mn |
| Mar 31, 2022 | -41.93 Mn |
| Dec 31, 2021 | 100.71 Mn |
| Sep 30, 2021 | -24.94 Mn |